Literature DB >> 27247400

Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques.

Hui Li1, Shuyi Wang1, Rui Kong1, Wenge Ding1, Fang-Hua Lee1, Zahra Parker1, Eunlim Kim1, Gerald H Learn1, Paul Hahn1, Ben Policicchio2, Egidio Brocca-Cofano2, Claire Deleage3, Xingpei Hao3, Gwo-Yu Chuang4, Jason Gorman4, Matthew Gardner5, Mark G Lewis6, Theodora Hatziioannou7, Sampa Santra8, Cristian Apetrei2, Ivona Pandrea2, S Munir Alam9, Hua-Xin Liao9, Xiaoying Shen9, Georgia D Tomaras9, Michael Farzan5, Elena Chertova3, Brandon F Keele3, Jacob D Estes3, Jeffrey D Lifson3, Robert W Doms10, David C Montefiori9, Barton F Haynes9, Joseph G Sodroski11, Peter D Kwong3, Beatrice H Hahn12, George M Shaw12.   

Abstract

Most simian-human immunodeficiency viruses (SHIVs) bearing envelope (Env) glycoproteins from primary HIV-1 strains fail to infect rhesus macaques (RMs). We hypothesized that inefficient Env binding to rhesus CD4 (rhCD4) limits virus entry and replication and could be enhanced by substituting naturally occurring simian immunodeficiency virus Env residues at position 375, which resides at a critical location in the CD4-binding pocket and is under strong positive evolutionary pressure across the broad spectrum of primate lentiviruses. SHIVs containing primary or transmitted/founder HIV-1 subtype A, B, C, or D Envs with genotypic variants at residue 375 were constructed and analyzed in vitro and in vivo. Bulky hydrophobic or basic amino acids substituted for serine-375 enhanced Env affinity for rhCD4, virus entry into cells bearing rhCD4, and virus replication in primary rhCD4 T cells without appreciably affecting antigenicity or antibody-mediated neutralization sensitivity. Twenty-four RMs inoculated with subtype A, B, C, or D SHIVs all became productively infected with different Env375 variants-S, M, Y, H, W, or F-that were differentially selected in different Env backbones. Notably, SHIVs replicated persistently at titers comparable to HIV-1 in humans and elicited autologous neutralizing antibody responses typical of HIV-1. Seven animals succumbed to AIDS. These findings identify Env-rhCD4 binding as a critical determinant for productive SHIV infection in RMs and validate a novel and generalizable strategy for constructing SHIVs with Env glycoproteins of interest, including those that in humans elicit broadly neutralizing antibodies or bind particular Ig germ-line B-cell receptors.

Entities:  

Keywords:  CD4; HIV-1 envelope; HIV/AIDS; SHIV

Mesh:

Substances:

Year:  2016        PMID: 27247400      PMCID: PMC4914158          DOI: 10.1073/pnas.1606636113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  114 in total

1.  Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.

Authors:  Barna Dey; Marie Pancera; Krisha Svehla; Yuuei Shu; Shi-Hua Xiang; Jeffrey Vainshtein; Yuxing Li; Joseph Sodroski; Peter D Kwong; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

2.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

3.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

Authors:  K A Reimann; J T Li; R Veazey; M Halloran; I W Park; G B Karlsson; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

4.  AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

Authors:  Matthew R Gardner; Lisa M Kattenhorn; Hema R Kondur; Markus von Schaewen; Tatyana Dorfman; Jessica J Chiang; Kevin G Haworth; Julie M Decker; Michael D Alpert; Charles C Bailey; Ernest S Neale; Christoph H Fellinger; Vinita R Joshi; Sebastian P Fuchs; Jose M Martinez-Navio; Brian D Quinlan; Annie Y Yao; Hugo Mouquet; Jason Gorman; Baoshan Zhang; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton; Peter D Kwong; Michael Piatak; Jeffrey D Lifson; Guangping Gao; Ronald C Desrosiers; David T Evans; Beatrice H Hahn; Alexander Ploss; Paula M Cannon; Michael S Seaman; Michael Farzan
Journal:  Nature       Date:  2015-02-18       Impact factor: 49.962

5.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962

6.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

7.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.

Authors:  Jesus F Salazar-Gonzalez; Maria G Salazar; Brandon F Keele; Gerald H Learn; Elena E Giorgi; Hui Li; Julie M Decker; Shuyi Wang; Joshua Baalwa; Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; M Brad Guffey; Katharine J Bar; Katie L Davis; Christina Ochsenbauer-Jambor; John C Kappes; Michael S Saag; Myron S Cohen; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Martin Markowitz; Peter Hraber; Alan S Perelson; Tanmoy Bhattacharya; Barton F Haynes; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

8.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

9.  Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences.

Authors:  Lawrence J Tartaglia; Hui-Wen Chang; Benjamin C Lee; Peter Abbink; David Ng'ang'a; Michael Boyd; Christy L Lavine; So-Yon Lim; Srisowmya Sanisetty; James B Whitney; Michael S Seaman; Morgane Rolland; Sodsai Tovanabutra; Jintanat Ananworanich; Merlin L Robb; Jerome H Kim; Nelson L Michael; Dan H Barouch
Journal:  PLoS Pathog       Date:  2016-02-05       Impact factor: 6.823

10.  Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies.

Authors:  Jinal N Bhiman; Colin Anthony; Nicole A Doria-Rose; Owen Karimanzira; Chaim A Schramm; Thandeka Khoza; Dale Kitchin; Gordon Botha; Jason Gorman; Nigel J Garrett; Salim S Abdool Karim; Lawrence Shapiro; Carolyn Williamson; Peter D Kwong; John R Mascola; Lynn Morris; Penny L Moore
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

View more
  118 in total

1.  Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression.

Authors:  José M Martinez-Navio; Sebastian P Fuchs; Shara N Pantry; William A Lauer; Natasha N Duggan; Brandon F Keele; Eva G Rakasz; Guangping Gao; Jeffrey D Lifson; Ronald C Desrosiers
Journal:  Immunity       Date:  2019-03-05       Impact factor: 31.745

2.  Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants.

Authors:  Mingkui Zhou; Michael Humbert; Muhammad M Mukhtar; Hanna B Scinto; Hemant K Vyas; Samir K Lakhashe; Siddappa N Byrareddy; Gregor Maurer; Swati Thorat; Joshua Owuor; Zhao Lai; Yidong Chen; Anthony Griffiths; Agnès-Laurence Chenine; Sanjeev Gumber; François Villinger; David Montefiori; Ruth M Ruprecht
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

Review 3.  What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection.

Authors:  Hana Golding; Surender Khurana; Marina Zaitseva
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

4.  Genetically barcoded SIV reveals the emergence of escape mutations in multiple viral lineages during immune escape.

Authors:  Taina T Immonen; Celine Camus; Carolyn Reid; Christine M Fennessey; Gregory Q Del Prete; Miles P Davenport; Jeffrey D Lifson; Brandon F Keele
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

Review 5.  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?

Authors:  P J Klasse; Gabriel Ozorowski; Rogier W Sanders; John P Moore
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

6.  Tackling HIV and AIDS: contributions by non-human primate models.

Authors:  Koen K A Van Rompay
Journal:  Lab Anim (NY)       Date:  2017-05-22       Impact factor: 12.625

7.  Structure of Simian Immunodeficiency Virus Envelope Spikes Bound with CD4 and Monoclonal Antibody 36D5.

Authors:  Guiqing Hu; Jun Liu; Kenneth H Roux; Kenneth A Taylor
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

8.  CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption.

Authors:  Justin Harper; Shari Gordon; Chi Ngai Chan; Hong Wang; Emily Lindemuth; Cristin Galardi; Shane D Falcinelli; Samuel L M Raines; Jenna L Read; Kevin Nguyen; Colleen S McGary; Michael Nekorchuk; Kathleen Busman-Sahay; James Schawalder; Colin King; Maria Pino; Luca Micci; Barbara Cervasi; Sherrie Jean; Andrew Sanderson; Brian Johns; A Alicia Koblansky; Heather Amrine-Madsen; Jeffrey Lifson; David M Margolis; Guido Silvestri; Katharine J Bar; David Favre; Jacob D Estes; Mirko Paiardini
Journal:  Nat Med       Date:  2020-03-16       Impact factor: 53.440

9.  Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer.

Authors:  Peng Zhang; Jason Gorman; Hui Geng; Qingbo Liu; Yin Lin; Yaroslav Tsybovsky; Eden P Go; Barna Dey; Tsion Andine; Alice Kwon; Mit Patel; Deepali Gururani; Ferzan Uddin; Christina Guzzo; Raffaello Cimbro; Huiyi Miao; Krisha McKee; Gwo-Yu Chuang; Loïc Martin; Francesca Sironi; Mauro S Malnati; Heather Desaire; Edward A Berger; John R Mascola; Michael A Dolan; Peter D Kwong; Paolo Lusso
Journal:  Cell Host Microbe       Date:  2018-06-13       Impact factor: 21.023

10.  Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.

Authors:  Kara Jensen; Myra Grace Dela Pena-Ponce; Michael Piatak; Rebecca Shoemaker; Kelli Oswald; William R Jacobs; Glenn Fennelly; Carissa Lucero; Katie R Mollan; Michael G Hudgens; Angela Amedee; Pamela A Kozlowski; Jacob D Estes; Jeffrey D Lifson; Koen K A Van Rompay; Michelle Larsen; Kristina De Paris
Journal:  Clin Vaccine Immunol       Date:  2017-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.